Liquidia Corp

CEO Jeff Rogers’ 25k‑share Rule 10b5‑1 sale shows disciplined liquidity, not panic—Liquidia’s strong fundamentals keep the stock poised for growth.

Insight on Liquidia Corp’s insider sale: despite a large Bloch sell, the stock’s bullish momentum and earnings outlook remain strong.

CEO Roger Jeffs’s frequent Rule 10b‑5 plan sales of Liquidia shares amid a price rally raise questions about leadership confidence and future strategy—watch how it could impact stock volatility.

CEO Roger Jeffs steadily sells 25k shares at $40–$42, keeping 46% stake while boosting investor confidence in Liquidia’s growth.

Liquidia Corp CEO Roger Jeffs sells 70k shares via Rule 10(b)(5)(1) plans, raising investor caution amid a 2.7% weekly gain and 211% year‑high price.

Liquidia insiders buy shares in a planned 10b‑5‑1 scheme, signalling confidence in its nanoparticle drug‑delivery platform ahead of key clinical milestones.

Insider buying in Liquidia amid volatility signals executives believe the stock is undervalued; learn how Russell’s recent purchase reflects long‑term confidence and what it means for investors.

Liquidia Corp’s Chief Business Officer sold 688 shares via a 10b5‑1 plan for tax efficiency—insider activity shows disciplined equity management, not loss of confidence.

Liquidia’s insider buying shows management confidence in its biopharma pipeline—key takeaways for investors and insight into future upside.